Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
MDA-MB-231 Topotecan
0.1
Topo I
Chemotherapy
 0.2009 0.02238
MDA-MB-231 Topotecan
0.31623
Topo I
Chemotherapy
 0.1137 0.01915
MDA-MB-231 Topotecan
1.0
Topo I
Chemotherapy
 0.0403 0.05541
MDA-MB-231 Topotecan
3.1623
Topo I
Chemotherapy
 -0.2759 0.30863
MDA-MB-231 Topotecan
10.0
Topo I
Chemotherapy
 -0.3241 0.26925
MDA-MB-231 Etoposide
0.0010833
Topo II
Chemotherapy
 0.9641 0.00326
MDA-MB-231 Etoposide
0.0033333
Topo II
Chemotherapy
 0.9681 -0.00063
MDA-MB-231 Etoposide
0.01
Topo II
Chemotherapy
 0.9649 -0.00443
MDA-MB-231 Etoposide
0.031667
Topo II
Chemotherapy
 0.9687 -0.00133
MDA-MB-231 Etoposide
0.1
Topo II
Chemotherapy
 0.8974 -0.00260
MDA-MB-231 Etoposide
0.31623
Topo II
Chemotherapy
 0.7892 0.00091
MDA-MB-231 Etoposide
1.0
Topo II
Chemotherapy
 0.3827 0.04729
MDA-MB-231 Etoposide
3.1623
Topo II
Chemotherapy
 0.1203 0.03259
MDA-MB-231 Etoposide
10.0
Topo II
Chemotherapy
 0.1255 0.01009
MDA-MB-231 Dasatinib
0.001
BCR/ABL
MAPK/nRTK
 0.8842 0.01109
MDA-MB-231 Dasatinib
0.0031623
BCR/ABL
MAPK/nRTK
 0.8032 0.01283
MDA-MB-231 Dasatinib
0.01
BCR/ABL
MAPK/nRTK
 0.7243 0.02129
MDA-MB-231 Dasatinib
0.031623
BCR/ABL
MAPK/nRTK
 0.5201 0.03419
MDA-MB-231 Dasatinib
0.1
BCR/ABL
MAPK/nRTK
 0.2336 0.08448
MDA-MB-231 Dasatinib
0.31623
BCR/ABL
MAPK/nRTK
 0.0769 0.12622
MDA-MB-231 Dasatinib
1.0
BCR/ABL
MAPK/nRTK
 0.0657 0.14677
MDA-MB-231 Dasatinib
3.1623
BCR/ABL
MAPK/nRTK
 0.0172 0.24249
MDA-MB-231 Dasatinib
10.0
BCR/ABL
MAPK/nRTK
 -0.1256 0.35859
MDA-MB-231 Trametinib
0.0001
MEK
MAPK/nRTK
 0.9350 0.00624
MDA-MB-231 Trametinib
0.00031623
MEK
MAPK/nRTK
 0.9574 0.01575